Regencell Bioscience HoldingsRGC -21.58%33 Market Cap is $4,232.83 Mil as of Jun. 25, 2026. GuruFocus rates RGC with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Regencell Bioscience Holdings ranks better than 91.98% on this metric.
Regencell Bioscience Holdings's quarterly market cap
increased
from Dec. 2024 ($64.28 Mil) to Jun. 2025 ($8,426.09 Mil) and
increased
from Jun. 2025 ($8,426.09 Mil) to Dec. 2025 ($10,384.27 Mil).
Regencell Bioscience Holdings's annual market cap
declined
from Jun. 2023 ($299.82 Mil) to Jun. 2024 ($43.72 Mil) but then
increased
from Jun. 2024 ($43.72 Mil) to Jun. 2025 ($8,426.09 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Regencell Bioscience Holdings's Enterprise Value for Today is $4,228.47 Mil.
Regencell Bioscience Holdings (NAS:RGC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Regencell Bioscience Holdings Market Cap Related Terms
Regencell Bioscience Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's Market Cap falls into.
Regencell Bioscience Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regencell Bioscience Holdings (RGC) has a Market Cap of $4,232.83 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regencell Bioscience Holdings and its competitors. According to the industry distribution chart, Regencell Bioscience Holdings ranks #82 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 8%.
Is Regencell Bioscience Holdings' Market Cap too high?
Regencell Bioscience Holdings' current Market Cap is $4,232.83 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Regencell Bioscience Holdings' value of $4,232.83 Mil is 1949.8% above this industry median. Based on the distribution chart, Regencell Bioscience Holdings ranks #82 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Market Cap compare to ELAN and NBIX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #82 out of 1023 companies for Market Cap. This places Regencell Bioscience Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.50. Regencell Bioscience Holdings' value of $4,232.83 Mil is 1949.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regencell Bioscience Holdings's current Market Cap of $4,232.83 Mil is 1949.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current Market Cap is $4,232.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Market Cap of $4,232.83 Mil. The current Market Cap is $4,232.83 Mil and 1949.8% above the Drug Manufacturers industry median of 206.50. Regencell Bioscience Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Market Cap is $4,232.83 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Business Description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
33GF Score
Get the complete analysis for RGC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
